MapLight Completes 307-Patient Schizophrenia and 161-Patient Autism Trials; Q1 Cash $395M
MapLight completed enrollment in its 307-patient Phase 2 ZEPHYR schizophrenia trial and 161-patient Phase 2 IRIS autism spectrum disorder study, with topline results due by mid-August 2026. The Phase 2 VISTA Alzheimer’s disease psychosis trial continues with ~300 participants, and the company ended Q1 with $395.2M cash funding operations through 2027.
1. Clinical Trial Enrollment
MapLight completed enrollment of 307 participants in the randomized, placebo-controlled Phase 2 ZEPHYR schizophrenia trial and 161 in the Phase 2 IRIS autism spectrum disorder study. Enrollment is ongoing in the ~300-participant Phase 2 VISTA Alzheimer’s disease psychosis trial, which received FDA Fast Track designation for treating hallucinations and delusions in ADP.
2. Financial Performance
The company closed Q1 with $395.2 million in cash, cash equivalents and investments, projected to fund operations through 2027. R&D expenses rose to $53.7 million from $19.8 million year-over-year and G&A costs increased to $10.8 million from $3.8 million, resulting in a net loss of $60.7 million versus $22.3 million.
3. Upcoming Milestones
Topline data from the ZEPHYR and IRIS trials are expected by mid-August 2026, while readouts for the VISTA Alzheimer’s disease psychosis trial are anticipated in the second half of 2027.